73 results about "Genetics predisposition" patented technology

A method and kit for predicting increased risk of sight-threatening diabetic retinopathy which includes isolating genomic DNA from a sample from a diabetic patient. The genetic polymorphism pattern for the genes IL-1A, IL-1B and IL-1RN is then identified in the DNA. The identified pattern is compared with control patterns of known polymorphisms, and patients expressing a genetic polymorphism pattern associated with increased risk of sight-threatening diabetic retinopathy are identified.

Described are non-invasive methods of detecting the presence of specific nucleic acid sequences as well as nucleic acid modifications and alterations by analyzing urine samples for the presence of transrenal nucleic acids. More specifically, the present invention encompasses methods of detecting specific fetal nucleic acid sequences and fetal sequences that contained modified nucleotides by analyzing maternal urine for the presence of fetal nucleic acids. The invention further encompasses methods of detecting specific nucleic acid modifications for the diagnosis of disease, such as cancer and pathogen infections, and detection of genetic predisposition to various disease. The invention specifically encompasses methods of analyzing specific nucleic acid modifications for the monitoring of cancer treatment. The invention further encompasses methods of analyzing specific nucleic acids in urine to track the success of transplanted cells, tissues and organs. The invention also encompasses methods for evaluating the effects of environmental factors and aging on the genome.

The present invention pertains to cannabinoid (CB) receptor inverse agonists and neutral antagonists, and especially CB1 and CB2 inverse agonists and neutral antagonists; such as, for example, certain pyrazole compounds; their use in the inhibition of osteoclasts (for example, the inhibition of the survival, formation, and / or activity of osteoclasts), and / or in the inhibition of bone resorption; their use in connection with treatment of bone disorders, such as conditions mediated by osteoclasts (e.g., increased osteoclast activity) and / or characterised by (e.g., increased) bone resorption, such as osteoporosis (e.g., osteoporosis not associated with inflammation; e.g., osteoporosis associated with a genetic predisposition, sex hormone deficiency, or ageing), cancer associated bone disease, and Paget's disease of bone.

The present invention is directed to methods for atherosclerosis risk reduction including initial risk stratification, goal setting, and goal attainment for patients with, or at risk for, atherosclerosis. The present invention may be embodied in a computer implemented software product, the modules and sub-routines resident on a computer or hand held device, allowing a physician to determine the best strategy for coronary artery disease prevention based on such risk assessment values as Framingham score, genetic predisposition, biomarker levels and atherosclerosis imaging scores. The software product is supported by a backend database containing risk assessment value scores for a patient population of known clinical outcome. The database may reside in a memory unit, such as a hard drive, of the computer or hand held device, or may be accessed remotely in a distributed computer environment.

Described herein are assays, kits and methods for treating depression, including the diagnosis and treatment of depression based on the determination of genetic predispositions towards inhibition or enhancement of Ca2+ / calmodulin-dependent protein kinase II (CaMKII). For example, described herein are methods and kits (including assays) for determining if one or more gene in an excitatory or inhibitory pathway for modulating CaMKII activity or expression is likely to be inhibited or enhanced by an SNP. Also described are methods and kits (including assays) for prescribing treatment based on the identification of SNPs that may modulate CaMKII.

The present invention relates to an in vitro method for diagnosing a genetic predisposition or susceptibility for a cardiovascular disease, condition or disorder in a mammal which comprises detecting of at least three particular single nucleotide polymorphisms (SNP) in a sample obtained from said mammal in at least one of a genomic locus-derived nucleic acid or fragment thereof of the loci APOB, APOE, ABCA1, CETP, LCAT, LIPC, LPL, LDLR, APOC2, APOA5, APOA4, APOC3, and APOA1. Furthermore, the present invention relates to the improved diagnosis that is based on the analysis of several haplotypes for the above-mentioned loci (i.e. a combination of said haplotypes).

This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions.

The present invention relates to methods of processing and / or enriching cells from a pregnant female. More particularly the invention provides methods for processing and / or enriching fetal cells from a pregnant female. The enriched fetal cells can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.

The present invention relates to a method of enriching free fetal nucleic acids from a cervical sample. The enriched fetal nucleic acids can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.

The present invention relates to a method of enriching fetal nuclei from a sample. Enriched fetal nuclei can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing.

A method of screening for a genetic predisposition to anticholinesterase exposure. The method includes the steps of obtaining a peripheral blood sample, and then analysing serum from the blood sample for BuChE levels and inhibitor-susceptibilities. The DNA of peripheral white blood cells from the blood sample is also screened for the presence of BuChE alleles thereby identifying patients who have a genetic predisposition to anticholinesterase exposure.

The invention discloses a PCR (Polymerase Chain Reaction) kit for detecting BRCA (Breast Cancer) genic mutation, which is characterized by comprising a plurality of primer pairs used for specifically amplifying a BRCA gene targeting sequence, wherein each primer pair contains a continuous nucleotide sequence formed by at least 15 continuous nucleotides in the 2nd exon of a BRCA1 gene or the 20th exon of the BRCA1 gene or the 11th exon of a BRCA2 gene; the 2nd exon of the BRCA1 gene has a continuous nucleotide sequence of SEQ ID No:1; the 20th exon of the BRCA2 gene has a continuous nucleotide sequence of SEQ ID No:2; and the 11th exon of the BRCA2 gene has a continuous nucleotide sequence of SEQ ID No:3. The kit completes the judgment on the sample genotype by adopting a saturation probe and a high resolution dissolution curve analyzing technology, thereby providing the guidance for medication selection and genetic predisposition of familial breast cancer and ovarian cancer.

The present invention relates to methods of treatment for Parkinson Disease (PD) in a person by identifying gene variants which may indicate a more favorable response to specific medicaments, thereby allowing for personalized or individualized treatment. The present invention relates to a method of screening for a genetic predisposition to PD in a person. The present invention is also directed to a method of testing a person for the presence of particular gene variants, wherein the presence of a gene variant indicates a higher predisposition to PD, and the absence of a gene variant indicates a lower predisposition to PD, compared to a control sample. The present invention further relates to methods and kits for treating, or inhibiting the development of, PD in a person. The present invention is also directed to a method of identifying the heritage of an individual based on the genetic profile of the individual.

The present invention provides compositions and methods for identifying a subject as having a genetic predisposition to obesity or at risk of developing obesity. The present invention also provides compositions and methods for expressing a CREBRF polypeptide of the invention in a cell or precursor thereof and cells expressing a nucleic acid molecule encoding a CREBRF polypeptide of the invention.

The invention discloses a kit that is used for genetic risk detection of individual angiocardiopathy as well as health evaluation and management. The kit comprises an electrophoresis detecting primer pair that is used for detecting rs4646994 SNP polymorphism genotype on the gene of angiotonin converting enzyme (ACE), particularity primer pairs and particularity fluorescent probe pairs that are used for detecting rs5186 SNP locus on the gene of angiotonin II-1 type receptor (AGTR1), rs5443 SNP locus on the gene of G protein 3 subunit (GNB3) and rs1799983 SNP locus on the gene of endothelial nitric oxide synthase (NOS3), a fluorescent quantitative PCR routine component, and a PCR reaction component, etc. The kit of the invention implements cardiovascular health evaluation of detected person by evaluating the generic risk of developing angiocardiopathy and makes a health management plan that satisfies the genetic predisposition of detected person according to the four SNP locus genotypes that related with the genetic risk of developing angiocardiopathy of the detected person.

The invention provides method of diagnosing a receptor tyrosine kinase (RTK)-hyperfunction-induced disorder or a genetic predisposition therefor in a mammal. The method comprises determining the presence of a nucleic acid encoding a mutated fibroblast growth factor receptor-4 (FGFR-4) protein in a nucleic acid sample from a mammal. The presence of a nucleic acid encoding a mutated FGFR-4 protein is indicative of an RTK-hyperfunction-induced disorder or a genetic predisposition therefor.

Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a Mexican-American human subject for developing insulin resistance and methods of detecting a lower than normal risk in a Mexican-American human subject for developing insulin resistance or coronary artery disease.

The invention discloses a method for detecting Marek's disease resistance homozygous genotype chicken, which comprises the following steps: adopting the PCR-RFLP technology to perform PCR amplification on the second exon of BLB2 genes of 99 MDV-1 toxin eliminated Xiayan chickens and perform Alu I, Cai I, Cfr I, Hinl I, Hinf I and Rsa I restriction enzyme analysis on the PCR products, and initially obtaining seven BLB2 allelic genes genotype chickens by performing the restriction analysis on the six loci; finally obtaining six BLB2 / BF2 allelic genes genotype chickens by sequencing the BLB2 and BF2 genes of the seven genotype chickens; and by combining the toxin-eliminating result, determining four MD resistance individuals. The established method can detect the MD resistance homozygous genotype chickens, and the MD resistance homozygous genotype chickens are taken as breeders to breed the MD resistance chickens. Therefore, the method has extremely great economic benefits to prevention and control of MD and related immune-suppressing diseases on genetic predisposition.

Systems and methods for mitigating prostate cancer development are provided. Peripheral blood cells may be evaluated for the presence or quantity of gamma-H2AX foci, and / or for gene alterations encoding a protein with impaired or lack of function, for example, because the encoded protein is truncated, and correlating with prostate cancer development. Such nucleic acids may encode proteins from or peripheral to the DNA damage repair pathway and / or androgen receptor signaling pathway, or that are otherwise correlated with prostate cancer development. Such genes include one or more of AKR1C1, PALB2, APTX, BLM, BRCA1, CTBP1, DDB2, FANCA, FANCL, MBD5, MSH3, NEIL3, RAD51D, RAD54L2, SP1, TP53BP1, UBE2D3, UBE2V2, NRIP1, EFCAB6, CRISP3, PAPSS2, ATP6V0A2, ALG13, MGAT2, B3GAT3, DOLK, FLT3, ASXL1, KDR, or NOTCH2.

Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T. brucei. The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and / or a deletion of N388 and Y389 to the subject.

Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a human subject for certain biological conditions, which may be related to coronary artery disease.

A method of identifying livestock animal subgroups of the same species, from a group of livestock animals of the same species wherein the subgroup has similar genetic predispositions for response to Zilpaterol Hydrochloride (ZH) treatment with respect to marbling, HCW gain, REA size gain, DDMI, % EBF, and YG's. The genetic potential of each animal to respond to ZH treatment is established by determining the LeptinArg25Cys genotype and segregating individual animals into subgroups based upon the LeptinArg25Cys genotype.

A method of predicting the presence of a non-functional BRCA1 gene in a biological sample, comprises the step of assaying the sample for expression of at least one specific member of the S100 family of genes. The invention also describes a kit for predicting the presence of non-functional BRCA1, comprising means for assaying a sample for expression of at least one specific member of the S100 gene family. A method of detecting a genetic predisposition to cancer is also described, comprising the step of assaying a biological sample for expression of a specific member of the S100 family of genes. Also described is a method of determining a suitable chemotherapeutic agent for an individual.

The invention relates to a kit for detecting VKH (Vogt Koyanagi Harada) syndrome. The kit contains primer pairs of a reagent used for amplifying gene segments at loci of rs78377598, rs77258390, rs78597810, rs12568393, rs12561798, rs76436269, rs3021304, rs442309 and rs224058 and a Sequenom MassARRAY single-base extension primer for specifically detecting idiotypes. The kit is used for predicating the genetic predisposition of a subject for the VKH syndrome by detecting whether the SNP (single nucleotide polymorphism) loci of the subject are varied, and can be used for early screening for the occurrence of the VKH syndrome of Chinese Han population and providing a basis for clinical diagnosis and treatment.

The invention relates to methods for diagnosing a genetic predisposition or susceptibility for anxiety disorders in a human. The methods include detecting particular markers at the human RGS2 locus in a sample obtained from the human. The invention also relates to the improved diagnosis that is based on the analysis of haplotypes for the RGS2 locus.

A method for improving efficiencies in livestock production comprises grouping livestock animals, such as cattle and pigs, during the period of their retention in a feeding facility according to the genetic predisposition of individual livestock animals to deposit fat, and then feeding the animals in each group substantially uniformly. Such genetic predisposition is determined by determining homozygosity or heterozygosity of each animal with respect to alleles of a gene encoding an adipocyte-specific polypeptide, termed leptin, which gene is hereinafter referred to as ob, segregating such animals into groups based on genotype and optionally phenotype, feeding and otherwise maintaining animals in a group together and apart from other groups of animals, and ceasing to feed the animals in the group at a time when the median body fat condition of the animals of that group is a desired body fat condition. Packers can also more accurately predict the fat deposition in carcasses of live animals it purchases, leading to increased efficiencies.

The invention relates to a precision nutrient meal replacement composition for preventing and treating gestational diabetes and an application method thereof. The precision nutrient meal replacement composition includes a basic preventing and treating bag, a metabolism improvement bag, a micronutrient supplement bag and a hypoglycemic medical and edible bag; the basic preventing and treating bag is composed of soy protein, coarse cereal powder and high oleic peanut oil; the metabolism improvement bag is composed of EPA and DHA; the micronutrient supplement bag is composed of composite mineralsubstances and composite vitamins, wherein the composite mineral substances include Zn, Se and Cr, and the composite vitamins include vitamin C, vitamin B1 and vitamin B2; the hypoglycemic medical andedible bag is composed of inulin, yam powder, tartary buckwheat seeds, lycii fructus, stigma maydis and lotus leaf extract. The application method of the precision nutrient meal replacement composition includes the step of using the basic preventing and treating bag independently or in combination with three other meal replacement bags. The precision nutrient meal replacement composition has theadvantages that different formula combinations are provided for women preparing for pregnancy, pregnant women and postpartum women according to different results of genetic predisposition detection and nutrition assessment, so that the purposes of preventing or treating gestational diabetes are achieved through precise nutrition intervention.

The invention discloses a kit for detecting individual oxidation resistance genetic predisposition, comprising: a specific primer pair for simultaneous detection of No.rs769214 SNP locus on catalase gene (CAT), No.rs4673 SNP locus on NADPH phytol gene (CYBA), No.rs1799983 SNP locus on endodermis NOS gene (NOS3), No.rs1799895 SNP locus on ectoenzyme peroxide dismutase gene (SOD3), and No.rs662 locus on paraoxonase-1 gene (PON1); a specific fluorescent probe pair; an ordinary component for fluorescent quantitative PCR detection, etc. The kit of the invention estimates individual oxidation resistance genetic predisposition by simultaneous detecting mononucleotide polymorphism locus genes of CAT, CYBA, NOS3, SOD3, PON1 closely related to the oxidation resistance ability.

A method and a kit for determining the human with genetic predisposition to increased consumption of carbohydrates and to develop metabolic, psychiatric or neurological disease or disorder, or obesity. The invention pertains to the detection of a human's ADRA2A genotype, and if there is detected the homozygous nucleotide G at the position C-1291 of the ADRA2A gene, then the patient possesses a predisposition to increased consumption of carbohydrates and to develop metabolic, psychiatric or neurological diseases or disorders or obesity, and there is a need to decrease intake of carbohydrates.

The methods of the present invention are based upon the gathering of information from various sources about animals. The information is based upon laboratory testing, genetic analysis and observations by owners and / or trainers about various traits that can be readily observed. Based upon this collection of information, one method generates Performance Index which scores or ranks an animal in terms of how well an animal might function for the intended purpose. Other methods include the ability to selection an optimum breeding pair from one or more stallions and / or one or more mares that would likely produce an offspring with the desired traits.